We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What is Lobular Carcinoma?

By L. Hepfer
Updated Mar 03, 2024
Our promise to you
The Health Board is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At The Health Board, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject-matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Lobular carcinoma is a type of cancer that attacks the breast in the lobular area, or milk glands, of the breast. Lobular carcinoma is the second most common type of breast cancer. It makes up approximately 10% of all breast cancer cases. There are two different types of lobular carcinoma.

Invasive lobular carcinoma (ILC) begins in the milk glands of the breast and eventually spreads to the surrounding tissues. It does not normally show up on a mammogram, however, it seems to have a better prognosis than other invasive cancers of the breast. The tumor in the breast tends to grow in the last part of the lobule glands. The tumor may feel like a thickening in the upper outer portion of the breast and may be found when a woman is performing a self examination of the breast.

The skin may pucker over the area where the tumor is located. Invasive lobular carcinoma often tests positive for estrogen or progesterone receptors and usually responds well to hormonal treatments. If it is not caught in an early stage and treated, this type of cancer may eventually spread to the woman's ovaries and uterus.

Lobular carcinoma in situ (LCIS) is a form of pre-invasive breast cancer and is often considered to be a precancerous condition of the breast. Abnormal cells have been discovered, however, this particular diagnosis means it has been discovered before the breast has been invaded by the cancer cells. During this stage the cancer cells have the ability to multiply but have not moved beyond the lobule lining and into other areas of the breast.

A woman who is diagnosed with lobular carcinoma in situ is at a greater risk of developing an invasive breast cancer later on. Other risk factors for developing breast cancers include a woman's age, a family history of breast cancer, exposure to radiation and varying hormonal factors. Checking the breast regularly for any unusual lumps, nipple discharge or changes in the skin increases a woman's chance of detecting any type of cancer in its early stages.

Receiving treatment for lobular carcinoma in situ will depend on each individual situation. Sometimes a physician will not recommend treatment for this condition since it is a precancerous condition. Instead, the physician will advise the patient to be clinically screened on a regular basis so any early signs of invasive breast cancer can be caught and treated. The benefits of cancer treatment will be weighed and compared with the risk of the treatment involved. Treatment may be sought to increase a patient's chance of recovery and prolong her survival.

The Health Board is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Discussion Comments
The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.

The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.